NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC
NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC

Axel Bex, MD, PhD, of the Netherlands Cancer Institute, gives an overview of the phase II NEOAVAX trial, which investigated avelumab/axitinib as a neoadjuvant therapy in patients with high-risk RCC.

Professor Bex breaks down the rationale for combining avelumab and axitinib in the neoadjuvant setting, the selection of endpoints and biomarkers in the exploratory analyses, and more.

Advertisement

Latest News

Bevacizumab and Erlotinib Combination May Help HLRCC-Linked Papillary RCC
Bevacizumab and Erlotinib Combination May Help HLRCC-Linked Papillary RCC
Jessica GanganccRCC | July 11, 2025
Phase 2 trial examines efficacy and response of bevacizumab/erlotinib for treatment of patients with rare subtypes of RCC.
PSA Anxiety and Patient Fears: Navigating De-escalation Conversations
PSA Anxiety and Patient Fears: Navigating De-escalation Conversations
Shahid S. Ahmed, MDmCSPC | July 10, 2025
Drs. Ahmed and Ciuro discuss the real-world quality-of-life improvements patients may experience after de-escalating therapy.
When Less Is More: Safe De-escalation in Oligometastatic Prostate Cancer
When Less Is More: Safe De-escalation in Oligometastatic Prostate Cancer
Shahid S. Ahmed, MDmCSPC | July 10, 2025
Drs. Ahmed and Ciuro explore the rationale and complexity behind treatment de-escalation in de novo oligometastatic HSPC.
Can PSMA PET Imaging Predict Lu-PSMA Outcomes?
Can PSMA PET Imaging Predict Lu-PSMA Outcomes?
Koichiro Kimura, MD, PhDRLT | July 8, 2025
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
Stereotactic Ablative Body Radiotherapy More Effective, Less Expensive for Patients With Inoperable RCC
Stereotactic Ablative Body Radiotherapy More Effective, Less Expensive for Patients With Inoperable RCC
Emily MenendezLocalized Renal Cell Carcinoma | July 8, 2025
Despite an initial decrease in HRQOL after SABR, the procedure is more effective and less expensive than RFA & ...
Intravesical Gemcitabine/Docetaxel as First-Line Therapy for Patients With NMIBC
Intravesical Gemcitabine/Docetaxel as First-Line Therapy for Patients With NMIBC
Jessica GangaNon-Muscle Invasive Urothelial Carcinoma | July 1, 2025
Researchers find promise in Gem/Doce as an alternative therapy for patients with NMIBC recurrence after BCG induction.
Targeting CD70 With ALLO-316 in Advanced Clear Cell RCC: Updated Phase 1 Results From TRAVERSE
Targeting CD70 With ALLO-316 in Advanced Clear Cell RCC: Updated Phase 1 Results From TRAVERSE
Samer Srour, MBAdvanced Renal Cell Carcinoma | June 30, 2025
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
CHAI vs Clinical Judgment: A New Frontier in NMIBC Personalization
CHAI vs Clinical Judgment: A New Frontier in NMIBC Personalization
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram conclude with an AI-powered pathology tool designed to predict response to BCG in NMIBC.
SunRISe-1 Cohort 4 and Papillary NMIBC Treatment
SunRISe-1 Cohort 4 and Papillary NMIBC Treatment
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram shift focus to SunRISe-1 Cohort 4, which examined BCG-unresponsive papillary disease.
Checkpoint Inhibitors Meet BCG: Interpreting the CREST Trial for NMIBC
Checkpoint Inhibitors Meet BCG: Interpreting the CREST Trial for NMIBC
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram contextualize recent data from the CREST trial, which evaluated sasanlimab with BCG for HR NMIBC.
The Innovation Dilemma: More NMIBC Therapies, But No Comparative Trials
The Innovation Dilemma: More NMIBC Therapies, But No Comparative Trials
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram focus on how agents like gem/doce, pembro, nadofaragene, cretostimogene, and TAR-200 are used.
Tailoring Treatment in NMIBC: From Tumor Biology to TAR-200
Tailoring Treatment in NMIBC: From Tumor Biology to TAR-200
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram discuss TAR-200 and the ongoing SunRISe-3 trial exploring its effectiveness amid BCG shortages.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Teaching TURBT Over 5G: Integrating XR Headsets Into Urologic Practice
Evan Kovac, MDProstate Cancer | May 19, 2025
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | June 25, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | June 25, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | June 25, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.

Conference Coverage

Live meeting highlights

Can PSMA PET Imaging Predict Lu-PSMA Outcomes?
Koichiro Kimura, MD, PhDRLT | July 8, 2025
Dr. Kimura shares insights on PSMA PET/CT metrics and their potential role in guiding treatment decisions for mCRPC.
View More
NEOAVAX Trial: Neoadjuvant Avelumab and Axitinib for Localized High-Risk RCC
Axel Bex, MD, PhDLocalized Renal Cell Carcinoma | July 1, 2025
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
View More
Targeting CD70 With ALLO-316 in Advanced Clear Cell RCC: Updated Phase 1 Results From TRAVERSE
Samer Srour, MBAdvanced Renal Cell Carcinoma | June 30, 2025
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
View More
Radiopharmaceutical Trials in Prostate Cancer: Evolving Treatments and Combination Therapies
Robert Flavell, MD, PhDRLT | June 27, 2025
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |